Amgen announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of Blincyto (blinatumomab) in patients with Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia who had failed at least one second-generation or later tyrosine kinase inhibitor.
The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School.Â
